For: | Avoranta ST, Korkeila EA, Syrjänen KJ, Pyrhönen SO, Sundström JTT. Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence. World J Gastroenterol 2012; 18(33): 4549-4556 [PMID: 22969228 DOI: 10.3748/wjg.v18.i33.4549] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v18/i33/4549.htm |
Number | Citing Articles |
1 |
Anna Dubrovska. Report on the International Workshop ‘Cancer stem cells: The mechanisms of radioresistance and biomarker discovery’. International Journal of Radiation Biology 2014; 90(8): 607 doi: 10.3109/09553002.2014.920968
|
2 |
淑芳 武. Research Progress of the Effect of Multimodal Analgesia on the Perioperative Immune Functions and Long-Term Survival for Patients with Lung Cancer. Advances in Clinical Medicine 2021; 11(04): 1518 doi: 10.12677/ACM.2021.114217
|
3 |
WEIYI SUN, GANG CHEN. Impact and mechanism of non-steroidal anti-inflammatory drugs combined with chemotherapeutic drugs on human lung cancer-nude mouse transplanted tumors. Oncology Letters 2016; 11(6): 4193 doi: 10.3892/ol.2016.4493
|
4 |
Ruixia Huang, Yuanyuan Ma, Ruth Holm, Claes G. Trope, Jahn M. Nesland, Zhenhe Suo, Viji Shridhar. Sex Hormone-Binding Globulin (SHBG) Expression in Ovarian Carcinomas and Its Clinicopathological Associations. PLoS ONE 2013; 8(12): e83238 doi: 10.1371/journal.pone.0083238
|
5 |
Tomoko Umeda, Mitsuaki Ishida, Satoshi Murata, Tsuyoshi Mori, Yuki Kawai, Naoko Itoi, Kaori Tomida, Akie Tanaka, Sachiko Sakai, Mina Kitamura, Yoshihiro Kubota, Ryoji Kushima, Masaji Tani. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component. Breast Cancer 2016; 23(6): 869 doi: 10.1007/s12282-015-0653-4
|
6 |
Tomoko Yamamoto, Atsuko Hiroi, Hiroko Itagaki, Yoichiro Kato, Bunei Iizuka, Michio Itabashi, Noriyuki Shibata, Yoji Nagashima. Well-differentiated adenocarcinoma associated with ulcerative colitis. SAGE Open Medical Case Reports 2017; 5 doi: 10.1177/2050313X17692902
|
7 |
Eva‐Maria Birkman, Adam Elzagheid, Terhi Jokilehto, Tuulia Avoranta, Eija Korkeila, Jarmo Kulmala, Kari Syrjänen, Jukka Westermarck, Jari Sundström. Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer. Cancer Medicine 2018; 7(3): 698 doi: 10.1002/cam4.1361
|
8 |
Pantea Rohani, Farahnaz Noroozinia, Parisa Modarresi, Ata Abbasi. CD44 Standard Isoform; Not a Good Marker for Colon Cancer. International Journal of Cancer Management 2017; 10(9) doi: 10.5812/ijcm.9166
|
9 |
Alaa Afify, Blythe Durbin-Johnson, Avnit Virdi, Heidi Jess. The expression of CD44v6 in colon: from normal to malignant. Annals of Diagnostic Pathology 2016; 20: 19 doi: 10.1016/j.anndiagpath.2015.10.010
|
10 |
H.-G. Liu, L. Lv, H. Shen. Intratumoral heterogeneity of CD44v6 in rectal cancer. Clinical and Translational Oncology 2017; 19(4): 425 doi: 10.1007/s12094-016-1542-9
|
11 |
Ji-Lin Wang, Wen-Yu Su, Yan-Wei Lin, Hua Xiong, Ying-Xuan Chen, Jie Xu, Jing-Yuan Fang. CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis. Oncotarget 2017; 8(8): 12866 doi: 10.18632/oncotarget.14163
|
12 |
Min Liu, Weiyue Lu. New Nanomaterials and Techniques for Tumor-targeted Systems. 2020; : 27 doi: 10.1007/978-981-15-5159-8_3
|
13 |
Mi Jin Gu, Byung Ik Jang. Clinicopathologic Significance of Sox2, CD44 and CD44v6 Expression in Intrahepatic Cholangiocarcinoma. Pathology & Oncology Research 2014; 20(3): 655 doi: 10.1007/s12253-014-9745-2
|
14 |
Anthony E. Rizzardi, Xiaotun Zhang, Rachel Isaksson Vogel, Suzanne Kolb, Milan S. Geybels, Yuet-Kin Leung, Jonathan C. Henriksen, Shuk-Mei Ho, Julianna Kwak, Janet L. Stanford, Stephen C. Schmechel. Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor β2 immunohistochemistry in prostate cancer. Diagnostic Pathology 2016; 11(1) doi: 10.1186/s13000-016-0511-5
|
15 |
Chenchen Qian, Yong Wang, Yinting Chen, Linjuan Zeng, Qiubo Zhang, Xintao Shuai, Kaihong Huang. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. Biomaterials 2013; 34(26): 6175 doi: 10.1016/j.biomaterials.2013.04.056
|
16 |
Rebecca Bütof, Anna Dubrovska, Michael Baumann. Clinical perspectives of cancer stem cell research in radiation oncology. Radiotherapy and Oncology 2013; 108(3): 388 doi: 10.1016/j.radonc.2013.06.002
|
17 |
Zhenpeng Wang, Yufei Tang, Lei Xie, Aiping Huang, Chunchun Xue, Zhen Gu, Kaiqiang Wang, Shaoqi Zong. The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00309
|
18 |
Chihiro Yoshida, Kyuichi Kadota, Kaede Yamada, Syusuke Fujimoto, Emi Ibuki, Ryou Ishikawa, Reiji Haba, Toshiki Yajima. CD44v6 downregulation as a prognostic factor for distant recurrence in resected stage I lung adenocarcinomas. Clinical and Experimental Medicine 2023; 23(8): 5191 doi: 10.1007/s10238-023-01185-z
|
19 |
Bruce M. Boman, Vignesh Viswanathan, Caroline O. B. Facey, Jeremy Z. Fields, James W. Stave. The v8-10 variant isoform of CD44 is selectively expressed in the normal human colonic stem cell niche and frequently is overexpressed in colon carcinomas during tumor development. Cancer Biology & Therapy 2023; 24(1) doi: 10.1080/15384047.2023.2195363
|